Centre Georges Francois Leclerc

This study tests adding a short course of a MEK inhibitor (mirdametinib) to standard chemoimmunotherapy for people with advanced non-squamous non-small cell lung cancer whose PDL1 is below 50%. The trial has two parts: first, finding the safest dose, then comparing the new combin…

This study looks for new genetic causes of cancer in people diagnosed at a young age (under 40, or under 30 for breast cancer). Standard genetic tests often miss the cause, so researchers will use a more detailed method called exome sequencing to search for hidden risk factors. T…

This study tests whether a more detailed analysis of a person's tumor DNA (complex exome analysis) helps doctors choose better treatments compared to a standard analysis. About 8,000 adults with advanced solid tumors will have their tumor genes read both ways. The goal is to see …